A Comprehensive Assessment to Predict Side Effects from Chemotherapy and an Evaluation of Pre-Phase Chemotherapy in Older Patients with Non-Hodgkin Lymphoma
[Protocol 13-028] |
Hamlin, Paul, MD |
A Long-Term Study of Sexual and Reproductive Health in Women with Breast Cancer and Lymphoma
[Protocol 12-249] |
Goldfarb, Shari, MD |
A Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and Stem Cell Transplantation in Patients with B-cell Non-Hodgkin's Lymphoma
[Protocol 06-150] |
Castro-Malaspina, Hugo, MD |
A Phase I Study of AEB071 in Patients with CD79-Mutant Diffuse Large B-Cell Lymphoma
[Protocol 12-157] |
Gerecitano, John, MD, PhD |
A Phase I Study of BMS-906024 in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma
[Protocol 11-181] |
Douer, Dan, MD |
A Phase I Study of BMS-936558 in Patients with Relapsed or Refractory Hematologic Cancers
[Protocol 12-142] |
Lesokhin, Alexander, MD |
A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
[Protocol 13-045] |
Younes, Anas, MD |
A Phase I Study of High-Dose Therapy and Autologous Stem Cell Transplantation Followed by Modified T Cells for Aggressive B-Cell Non-Hodgkin Lymphoma
[Protocol 12-117] |
Sauter, Craig, MD |
A Phase I Study of IPI-145 in Patients with Advanced Hematologic Cancers
[Protocol 12-088] |
Horwitz, Steven, MD |
A Phase I Study of Ipilimumab in Children, Adolescents, and Young Adults with Treatment-Refractory Cancer
[Protocol 10-193] |
Wexler, Leonard, MD |
A Phase I Study of Oral LEE011 in Patients with Advanced Solid Tumors or Lymphomas
[Protocol 10-211] |
Gerecitano, John, MD, PhD |
A Phase I Study of PF-05082566 Alone in Patients with Advanced Cancer, and in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
[Protocol 11-085] |
Segal, Neil, MD, PhD |
A Phase I Study of PU-H71 in Patients with Advanced Cancer
[Protocol 11-041] |
Gerecitano, John, MD, PhD |
A Phase I Study of SGN-CD19A in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
[Protocol 12-282] |
Moskowitz, Craig, MD |
A Phase I Study of Xenogeneic CD20 DNA Vaccination in Patients with B-cell Lymphoma
[Protocol 07-100] |
Palomba, M. Lia, MD |
A Phase I/II Study of Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Patients with Relapsed/Refractory Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
[Protocol 05-103] |
Gerecitano, John, MD, PhD |
A Phase I/II Study of Brentuximab (SGN-35) in Pediatric Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma or Hodgkin Lymphoma
[Protocol 11-210] |
Trippett, Tanya, MD |
A Phase I/II Study of EPOCH Chemotherapy, Bortezomib, and Raltegravir for the Treatment of HTLV-1-Associated T-Cell Leukemia/Lymphoma
[Protocol 12-146] |
Noy, Ariela, MD |
A Phase I/II Study of Sequential Chemoradiation Followed by Autologous Stem Cell Transplant in Patients with Untreated Advanced Mantle Cell Lymphoma
[Protocol 11-095] |
Zelenetz, Andrew, MD, PhD |
A Phase I/II Study of the Toxic and Therapeutic Effects of T Cells in the Treatment of Epstein Barr Virus-Associated Lymphoproliferative Disorders
[Protocol 95-024] |
O'Reilly, Richard, MD |
A Phase I/II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma
[Protocol 11-013] |
Noy, Ariela, MD |
A Phase IB/IIA Study of ABT-888 in Combination with Bendamustine with or without Rituximab in Patients with Lymphoma, Multiple Myeloma, and Solid Tumors
[Protocol 10-174] |
Gerecitano, John, MD, PhD |
A Phase IB/IIA Study of Romidepsin plus Lenalidomide in Adults with Relapsed or Refractory Lymphoma and Myeloma
[Protocol 12-170] |
Horwitz, Steven, MD |
A Phase II Study Evaluating the Use of Donated EBV-Immune T Cells to Treat Transplant Recipients with EBV
[Protocol 11-130] |
O'Reilly, Richard, MD |
A Phase II Study of Brentuximab (SGN-35) Given Before and After Adriamycin, Vinblastine, and Dacarbazine Therapy in Older Adults with Untreated Hodgkin Lymphoma
[Protocol 11-201] |
Hamlin, Paul, MD |
A Phase II Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
[Protocol 12-035] |
Horwitz, Steven, MD |
A Phase II Study of Bulk Versus Fractionated Stem Cell Infusions in Patients with Hematologic Cancers Undergoing Stem Cell Transplantation
[Protocol 12-016] |
Giralt, Sergio, MD |
A Phase II Study of Combination Chemotherapy with and without Low-Dose Whole-Brain Radiation for Primary Central Nervous System Lymphoma
[Protocol 11-125] |
Omuro, Antonio, MD |
A Phase II Study of Dose-Adjusted EPOCH Chemotherapy with or without Rituximab in Patients with Untreated Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, or Plasmablastic Lymphoma
[Protocol 13-022] |
Noy, Ariela, MD |
A Phase II Study of KW-0761 or Standard Therapy in Patients with Previously Treated Adult T-Cell Leukemia-Lymphoma
[Protocol 12-251] |
Horwitz, Steven, MD |
A Phase II Study of MLN8237 in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
[Protocol 12-096] |
Horwitz, Steven, MD |
A Phase II Study of Palifermin with or without Leuprolide After T-Cell-Depleted Allogeneic Stem Cell Transplantation
[Protocol 12-077] |
Goldberg, Jenna, MD |
A Phase II Trial of Transplants from HLA-Compatible Donors with T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System for the Treatment of Patients with Hematologic Malignancies and Disorders
[Protocol 10-050] |
O'Reilly, Richard, MD |
A Phase III Study of Ibritumomab Tiuxetan versus Observation in Older Patients with Diffuse Large B-Cell Lymphoma in Remission following R-CHOP
[Protocol 12-061] |
Hamlin, Paul, MD |
A Phase III Study of Inotuzumab Ozogamicin with Rituximab versus Standard Therapy for Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
[Protocol 12-005] |
Hamlin, Paul, MD |
A Phase III Study of KW-0761 versus Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma
[Protocol 13-007] |
Moskowitz, Alison, MD |
A Phase III Study of Ofatumumab versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
[Protocol 11-079] |
Matasar, Matthew, MD |
A Phase III Study of Rituximab/Lenalidomide or Rituximab/Chemotherapy Followed by Rituximab Maintenance Therapy in Patients with Previously Untreated Follicular Lymphoma
[Protocol 12-081] |
Palomba, M. Lia, MD |
A Study of Allogeneic Stem Cell Transplantation in HIV-Infected Patients with Hematologic Cancers
[Protocol 12-092] |
Sauter, Craig, MD |
A Study of Bortezomib plus (R)ICE in Subjects with Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
[Protocol 09-063] |
Noy, Ariela, MD |
A Study of Physician Communication Skills to Promote Patients' Transition to Survivorship
[Protocol 11-180] |
Horwitz, Steven, MD |
A Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin's Lymphoma
[Protocol 07-147] |
Perales, Miguel-Angel, MD |
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
[Protocol 00-069] |
Offit, Kenneth, MD |
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLA-Compatible Donor
[Protocol 12-053] |
O'Reilly, Richard, MD |
Brentuximab (SGN-35) in Transplant-Eligible Patients with Relapsed or Refractory Hodgkin Lymphoma
[Protocol 11-142] |
Moskowitz, Alison, MD |
Cyclophosphamide, Fludarabine, and Total Body Irradiation Followed by the Transplantation of Unrelated Double-Unit Donor Umbilical Cord Blood Grafts for Patients with Hematological Malignancy
[Protocol 06-014] |
Barker, Juliet, MBBS |
High-Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B-Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients
[Protocol 10-181] |
Noy, Ariela, MD |
Ofatumumab with or without Bendamustine for Patients with Mantle Cell Lymphoma Who Cannot Have an Autologous Stem Cell Transplant
[Protocol 11-050] |
Hamlin, Paul, MD |
PDX-017: A Phase III Study of Pralatrexate Versus Observation in Patients with Peripheral T-Cell Lymphoma Following Initial Chemotherapy
[Protocol 10-212] |
Horwitz, Steven, MD |
Risk-Adapted Therapy for Patients With Untreated Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B-Cell Lymphoma
[Protocol 08-026] |
Moskowitz, Craig, MD |
